Jun 2026 (Q2 FY26) — Aug 5, 2026
Geron Q2 FY26 — Strong RYTELO Revenue Growth and Pipeline Progress
Read the full callGeron (GERN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Geron earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 57.5 | +17.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -21.7 | +3.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -16.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.2 +2.56% · +$0.03
Performance 0.0% 1Y
1Y: $1.2 on 17 Oct 2025 → $1.2. High $1.95 (24 Feb 2026), low $1.07 (7 Nov 2025).
- Previous close
- $1.17
- 52-week range
- $1.07 – $1.95
- One year
- −5.51%
Overview
- Symbol
- GERN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Geron earnings calls (GERN)
Financials
What the filings say
Net profit, year on year: −2% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 28 | — | 40 | 49 | 47 | — | 52 | 57 |
| Operating profit | -28 | -20 | -17 | -12 | -14 | -26 | 0 | -12 |
| Operating margin | −99.8% | — | −42.2% | −25.4% | −29.4% | — | 0.3% | −21.7% |
| Interest | 3 | 9 | 8 | 9 | 9 | 7 | 7 | 7 |
| Net profit | -26 | -25 | -20 | -16 | -18 | -29 | -4 | -17 |
| EPS ($ per share) | -0.04 | — | -0.03 | -0.02 | -0.03 | — | -0.01 | -0.02 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Reserves | -1,011 | -1,080 | -1,156 | -1,272 | -1,414 | -1,598 | -1,772 | -1,856 |
| Total liabilities | 8 | 30 | 60 | 100 | 111 | 146 | 313 | 345 |
| Fixed assets | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total assets | 185 | 166 | 271 | 226 | 191 | 394 | 594 | 571 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -21 | -44 | -67 | -96 | -127 | -168 | -219 | -111 |
| Cash from investing | -78 | 27 | -105 | 72 | 62 | -180 | -106 | 107 |
| Cash from financing | 93 | 19 | 168 | 49 | 87 | 362 | 334 | 2 |
| Net cash flow | — | — | — | 25 | 22 | 14 | 10 | -1 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -1 | -1 | — |
| Free cash flow | -21 | -44 | -67 | -96 | -128 | -169 | -219 | — |
Insider filings
6 filings between Dec 31, 2025 and Sep 30, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$19.1K
1 sale by 1 insider
Compensation
not trading decisions- 4
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| ROBERTSON MICHELLE | — | $19.1K | Feb 18, 2026 |
Latest filings (17)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Spiegel Robert J. Director | Award | 6,351 | $7.8K |
| Jun 30, 2026 | Spiegel Robert J. Director | Award | 6,103 | $7.8K |
| Mar 31, 2026 | Spiegel Robert J. Director | Award | 5,243 | $7.8K |
| Feb 18, 2026 | ROBERTSON MICHELLE EVP, CHIEF FINANCIAL OFFICER | Sale | 9,855 | $19.1K |
| Feb 18, 2026 | ROBERTSON MICHELLE EVP, CHIEF FINANCIAL OFFICER | Option exercise | 27,500 | $0 |
| Dec 31, 2025 | Spiegel Robert J. Director | Award | 5,918 | $7.8K |
| Sep 30, 2025 | Spiegel Robert J. Director | Award | 5,702 | $7.8K |
| Jun 30, 2025 | Spiegel Robert J. Director | Award | 5,540 | $7.8K |
| May 9, 2025 | LAWLIS V BRYAN Director | Purchase | 13,300 | $15.7K |
| Mar 31, 2025 | Spiegel Robert J. Director | Award | 4,913 | $7.8K |
| Feb 27, 2025 | Ziegler James EVP, Chief Commercial Officer | Purchase | 100,000 | $160.0K |
| Feb 27, 2025 | SCARLETT JOHN A Chairman, President and CEO | Purchase | 12,500 | $22.1K |
| Feb 27, 2025 | Samuels Scott Alan EVP, Chief Legal Officer | Purchase | 15,000 | $24.1K |
| Dec 31, 2024 | Spiegel Robert J. Director | Award | 2,206 | $7.8K |
| Sep 30, 2024 | Spiegel Robert J. Director | Award | 1,767 | $8.0K |
| Jun 28, 2024 | Spiegel Robert J. Director | Award | 1,916 | $8.1K |
| Mar 29, 2024 | Spiegel Robert J. Director | Award | 2,462 | $8.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for GERON CORP
Free account. Everything above stays public.
Write why you follow GERON CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading